A/H7N9
Phase 2Biologic
A/H7N9 is one of 9 biologic programs targeting Avian Influenza. It is currently in Phase 2.
1
Indications
3
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Avian Influenza
#DrugCompanyPhaseTrials
1Fluzone
SanofiPhase 3
H5N1 Pisv
NNational Institute of Allergy and Infectious Diseases (NIAID)
Approved
Tamiflu
CConrado Roberto Hoffmann Filho
Phase 2
MF59
NovartisPhase 2
A/H7N9
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 2
Ad4-H5-Vtn
Emergent BioSolutionsPhase 1
Recombinant Influenza Hemagglutinin
VVaxine Pty Ltd
Phase 1
Influenza A/H5N1
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 1
ND1.1
VVaxart
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Vaccination1 trial
2017 A/H7N9 IIV Revaccination
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03738241·304 enrolled
Avian Influenza1 trial
Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03682120·372 enrolled
Unspecified1 trial
2013/2017 H7N9 Prime-Boost Interval
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03589807·180 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for A/H7N9. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details